Replies to post #170982 on Biotech Values

[biomaven0]

>>not a hint of cardiovascular issues

You left out my "except for hypertension" continuation.

There are multiple possible explanations - likely a combination of these is what is going on:

1. The cardiovascular stuff just doesn't show up as much in front line patients

2. They didn't specifically look for peripheral arterial disease - if you don't look you won't know about it until it bites you.

3. Just not enough time on drug. The key here is that the acceptable event rate for an acute treatment is very different than for a chronic drug that you need to take for years.

Realistically, the drug is very likely dead as a front line treatment, so maybe this is moot.

Peter